Cellular and molecular pathobiology of heart failure with preserved ejection fraction

S Mishra, DA Kass - Nature Reviews Cardiology, 2021 - nature.com
Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart
failure worldwide, is increasing in prevalence, confers substantial morbidity and mortality …

Metabolic inflammation in heart failure with preserved ejection fraction

GG Schiattarella, D Rodolico, JA Hill - Cardiovascular research, 2021 - academic.oup.com
One in 10 persons in the world aged 40 years and older will develop the syndrome of
HFpEF (heart failure with preserved ejection fraction), the most common form of chronic …

Endothelial cell dysfunction and increased cardiovascular risk in patients with chronic kidney disease

CC Baaten, S Vondenhoff, H Noels - Circulation Research, 2023 - Am Heart Assoc
The endothelium is considered to be the gatekeeper of the vessel wall, maintaining and
regulating vascular integrity. In patients with chronic kidney disease, protective endothelial …

[HTML][HTML] Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers

JA Borovac, D D'Amario, J Bozic… - World journal of …, 2020 - ncbi.nlm.nih.gov
Heart failure (HF) is a complex clinical syndrome characterized by the activation of at least
several neurohumoral pathways that have a common role in maintaining cardiac output and …

Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of …

SH Park, E Belcastro, H Hasan, K Matsushita… - Cardiovascular …, 2021 - Springer
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced cardiovascular risk
in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) …

JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction

S Hokimoto, K Kaikita, S Yasuda, K Tsujita… - Circulation …, 2023 - jstage.jst.go.jp
In 2008, the Guidelines for diagnosis and treatment of patients with vasospastic angina
(coronary spastic angina) 1 were developed by the Japanese Circulation Society, and the …

[HTML][HTML] Roles and mechanisms of renalase in cardiovascular disease: A promising therapeutic target

Y Li, W Wu, W Liu, M Zhou - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Cardiovascular disease (CVD) is prevalent worldwide and remains a leading cause of
death. Although substantial progress has been made in the diagnosis and treatment of CVD …

Exploring the complex relationship between diabetes and cardiovascular complications: understanding diabetic cardiomyopathy and promising therapies

N Ghosh, L Chacko, H Bhattacharya, J Vallamkondu… - Biomedicines, 2023 - mdpi.com
Diabetes mellitus (DM) and cardiovascular complications are two unmet medical
emergencies that can occur together. The rising incidence of heart failure in diabetic …

[HTML][HTML] Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction

S Shen, J Duan, J Hu, Y Qi, L Kang, K Wang… - European Journal of …, 2022 - Elsevier
Purpose Several studies have reported that colchicine attenuates cardiac inflammation and
improves cardiac function in myocardial infarction and atrial fibrillation. However, no study …

Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies

N Hamdani, S Costantino, A Mügge… - European heart …, 2021 - academic.oup.com
Described as the 'single largest unmet need in cardiovascular medicine', heart failure with
preserved ejection fraction (HFpEF) remains an untreatable disease currently representing …